Martínez Erro, SamuelNavas, FranciscoRomaní Cubells, EvaFernández García, PalomaMorales, VictoriaSanz, RaúlGarcía Muñoz, Rafael Á.2024-05-212024-05-212021-07-26 Samuel Martinez-Erro, Francisco Navas (coautor), Eva Romaní-Cubells, Paloma Fernández-García, Victoria Morales, Raúl Sanz, Rafael A. García Muñoz. International Journal of Molecular Sciences 2021, 22, 7968.1422-0067https://hdl.handle.net/10115/33021Este artículo describe la síntesis y caracterización de nanopartículas silíceas mesoporosas que contienen un derivado de cilastatina, un fármaco que protege al riñón de la acumulación de algunos agentes quimioterápicos en tratamientos de cáncer.Mesoporous silica nanomaterials have emerged as promising vehicles in controlled drug delivery systems due to their ability to selectively transport, protect, and release pharmaceuticals in a controlled and sustained manner. One drawback of these drug delivery systems is their preparation procedure that usually requires several steps including the removal of the structure-directing agent (surfactant) and the later loading of the drug into the porous structure. Herein, we describe the preparation of mesoporous silica nanoparticles, as drug delivery systems from structure-directing agents based on the kidney-protector drug cilastatin in a simple, fast, and one-step process. The concept of drug-structure-directing agent (DSDA) allows the use of lipidic derivatives of cilastatin to direct the successful formation of mesoporous silica nanoparticles (MSNs). The inherent pharmacological activity of the surfactant DSDA cilastatin-based template permits that the MSNs can be directly employed as drug delivery nanocarriers, without the need of extra steps. MSNs thus synthesized have shown good sphericity and remarkable textural properties. The size of the nanoparticles can be adjusted by simply selecting the stirring speed, time, and aging temperature during the synthesis procedure. Moreover, the release experiments performed on these materials afforded a slow and sustained drug release over several days, which illustrates the MSNs potential utility as drug delivery system for the cilastatin cargo kidney protector. While most nanotechnology strategies focused on combating the different illnesses this methodology emphasizes on reducing the kidney toxicity associated to cancer chemotherapy.engAttribution 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/mesoporous silica nanoparticles (MSNs); drug-structure-directing agent (DSDA); cilastatin; drug delivery systems; sustained and controlled releaseinfo:eu-repo/semantics/article10.3390/ijms22157968info:eu-repo/semantics/openAccess